Gate Neurosciences, Inc   Report issue

For profit Phase 1
Founded: Carmel IN United States (2018)

Organization Overview

First Clinical Trial
2018
NCT04981561
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Gate Neurosciences, Inc | Ronald M Burch MD PhD

Active Ingredients

Drugs in Phase 1 Trials (3)

gate-101 (1 trial)

nrx-1074 (1 trial)

Zelquistinel (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Depression (Phase 1)

Depressive Disorder (Phase 1)

Depressive Disorder, Major (Phase 1)

Sleepiness (Phase 1)

Overview

  • Highest Phase: Phase 1
  • # of Trials: 3
  • # of Trial APIs: 3